Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics ; volume:13 ; number:1 ; day:9 ; month:4 ; year:2024 ; pages:1-6 ; date:12.2024
Translational neurodegeneration ; 13, Heft 1 (9.4.2024), 1-6, 12.2024

Creator
Moutinho, Daniela
Mendes, Vera M.
Caula, Alessandro
Madeira, Sara C.
Baldeiras, Inês
Guerreiro, Manuela
Cardoso, Sandra
Gobom, Johan
Zetterberg, Henrik
Santana, Isabel
Mendonça, Alexandre De
Aidos, Helena
Manadas, Bruno
Contributor
SpringerLink (Online service)

DOI
10.1186/s40035-024-00412-1
URN
urn:nbn:de:101:1-2406241214014.286216504470
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:56 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Moutinho, Daniela
  • Mendes, Vera M.
  • Caula, Alessandro
  • Madeira, Sara C.
  • Baldeiras, Inês
  • Guerreiro, Manuela
  • Cardoso, Sandra
  • Gobom, Johan
  • Zetterberg, Henrik
  • Santana, Isabel
  • Mendonça, Alexandre De
  • Aidos, Helena
  • Manadas, Bruno
  • SpringerLink (Online service)

Other Objects (12)

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Related objects